Adalimumab for the treatment of psoriatic arthritis

References

• Leonard DG, O’Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin. Proc.53(8), 511–518 (1978).
   PubMed Web of Science ®Google Scholar
• Shbeeb M, Uramoto KM, Gibson LE, O’Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J. Rheumatol.27(5), 1247–1250 (2000).
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Gladman DD, Mease PJ et al. Epidemiology of psoriatic arthritis in the population of the United States. J. Am. Acad. Dermatol.53(4), 573 (2005).
   PubMed Web of Science ®Google Scholar
• Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum.61(2), 233–239 (2009).
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Gladman DD et al. Treatment recommendations for psoriatic arthritis. Ann. Rheum. Dis.68(9), 1387–1394 (2009).
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum.52(4), 1227–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis.64(8), 1150–1157 (2005).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum.50(7), 2264–2272 (2004).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum.52(10), 3279–3289 (2005).
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum.60(4), 976–986 (2009).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum.54(5), 1638–1645 (2006).
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet373(9664), 633–640 (2009).
   PubMed Web of Science ®Google Scholar
• Papp KA, Caro I, Leung HM, Garovoy M, Mease PJ. Efalizumab for the treatment of psoriatic arthritis. J. Cutan. Med. Surg.11(2), 57–66 (2007).
   PubMed Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Braun J. Adalimumab for the treatment of ankylosing spondylitis. Expert Opin. Pharmacother.8(6), 831–838 (2007).
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther.117(2), 244–279 (2008).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann. Rheum. Dis.66(2), 163–168 (2007).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mease PJ, Thomson GT et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J. Rheumatol.34(5), 1040–1050 (2007).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Ritchlin CT et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum.56(2), 476–488 (2007).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ory P, Sharp JT et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann. Rheum. Dis.68(5), 702–709 (2009).
   PubMed Web of Science ®Google Scholar
• van den Bosch F, Manger B, Goupille P et al. Adalimumab (Humira®) is effective in treating patients with psoriatic arthritis (PsA) in real life clinical practice: results of the STEREO trial. Ann. Rheum. Dis.66(Suppl. II), 98 (2008).
   Google Scholar
• Anandarajah AP, Ory P, Salonen D, Feng C, Wong RL, Ritchlin CT. Effect of adalimumab on joint disease features of patients with psoriatic arthritis detected by Magnetic Resonance Imaging. Ann. Rheum. Dis. (2009) (Epub ahead of print).
   Google Scholar
• van Kuijk AW, Gerlag DM, Vos K et al. A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann. Rheum. Dis.68(8), 1303–1309 (2009).
   PubMed Web of Science ®Google Scholar
• Heiberg MS, Koldingsnes W, Mikkelsen K et al. The comparative one-year performance of anti-tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum.59(2), 234–240 (2008).
   PubMed Web of Science ®Google Scholar
• Burmester GR, Mease PJ, Dijkmans BA et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann. Rheum. Dis. (2009) (Epub ahead of print).
   Google Scholar
• Rudwaleit M, Claudepierre P, Wordsworth P et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J. Rheumatol.36(4), 801–808 (2009).
   PubMed Web of Science ®Google Scholar
• Papoutsaki M, Costanzo A, Chimenti MS et al. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. Expert Opin. Biol. Ther.8(3), 363–370 (2008).
   PubMed Web of Science ®Google Scholar